Home › European Commission Grants Marketing Authorization for Gilead's...
 

Keywords :   


European Commission Grants Marketing Authorization for Gilead's...

2014-11-19 12:58:48| Biotech - Topix.net

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Harvoni , the first once-daily single tablet regimen to treat the majority of chronic hepatitis C genotype 1 and 4 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir with the nucleotide analog polymerase inhibitor sofosbuvir , approved by the European Commission under the tradename Sovaldi in January 2014.

Tags: marketing european commission grants

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
12.10Atlantic Tropical Weather Outlook
12.10Eastern North Pacific Tropical Weather Outlook
12.10Remnants of Leslie Graphics
12.10Remnants of Leslie Forecast Discussion Number 41
12.10Remnants of Leslie Wind Speed Probabilities Number 41
12.10Remnants of Leslie Public Advisory Number 41
12.10Summary for Remnants of Leslie (AT3/AL132024)
12.10Remnants of Leslie Forecast Advisory Number 41
More »